Hemab Therapeutics Holdings, Inc. 8K

Hemab Therapeutics announced Q2 2026 results and a robust pipeline update, including FDA-cleared progression of sutacimig to Phase 3 in Glanzmann thrombasthenia, new HMB-002 VWD data, and launch of the HMB-003 program, supported by IPO-boosted cash runway into 2029.

On August 11, 2026, Hemab Therapeutics Holdings, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a corporate update highlighting multiple clinical and preclinical developments across its bleeding disorder pipeline, including positive long-term extension Phase 2 data for sutacimig in Glanzmann thrombasthenia and FDA endorsement to proceed to a Phase 3 pivotal GT trial in 2H 2026, ongoing Phase 2 work in Factor VII deficiency, encouraging first-in-human data for HMB-002 in Von Willebrand Disease showing strong proof of mechanism and reduced treated bleeds, and the unveiling of a new antifibrinolytic program, HMB-003, aimed initially at heavy menstrual bleeding with first-in-human studies planned for 2H 2026, alongside disclosure that its recent IPO proceeds have strengthened its cash position to $457.5 million, expected to fund operations into 2029 despite continued operating losses.

Filing Facts

CIK

2114044

Ticker

COAG

Form

8K

Source Type

fda

Accession

0001193125-26-343421

Alert Tier

6